Drug Trial Radar · NCT07441200
Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Sep 29, 2026
Primary completion
Aug 1, 2028
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- NS Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Nippon Shinyaku Co., Ltd.
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH)
Conditions
- Pulmonary Arterial Hypertension
Interventions
NS-863 Low DoseDrug
NS-863 is an orally administered drug
NS-863 High DoseDrug
NS-863 is an orally administered drug
NS-863 PlaceboDrug
An orally administered NS-863 matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in pulmonary vascular resistance (PVR) at week 24Time frame: From baseline to week 24
- Number of participants who experienced an adverse event (AE) up to approximately 24 weeks.Time frame: From baseline to week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital of the University of Occupational and Environmental Health
Kitakyushu, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.